Share This Author
Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.
- G. Mayer, S. Wang-Weigand, B. Roth-Schechter, R. Lehmann, C. Staner, M. Partinen
- Medicine, PsychologySleep
- 1 March 2009
In adults with chronic insomnia, long-term ramelteon treatment consistently reduced sleep onset, with no next-morning residual effects or rebound insomnia or withdrawal symptoms upon discontinuation.
Effects of prolonged‐release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers
A prolonged‐release formulation of melatonin (PR‐M) that essentially mimics the profile of the endogenous production of the hormone is effective in the treatment of insomnia in patients aged 55 years and older.
Sleep microstructure around sleep onset differentiates major depressive insomnia from primary insomnia
The present results suggest that hyperarousal (high ‘Process W’) may mainly be implicated in the sleep initiation difficulties of primary insomniacs whereas the homeostatic sleep regulation process seems to be partially maintained.
Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia.
MIN-101 demonstrated statistically significant efficacy in reducing negative symptoms and good tolerability in stable schizophrenia patients and similar effects on several of the secondary outcome measures.
Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia
It is demonstrated that sublingual zolpidem is superior to an equivalent dose of oral zolPidem in terms of sleep inducing properties in a carefully selected sample of primary insomnia patients.
Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia.
- S. Deacon, L. Staner, C. Staner, A. Legters, H. Loft, J. Lundahl
- Psychology, MedicineSleep
- 1 March 2007
Gaboxadol 15 mg was effective and generally well tolerated in the short-term treatment of patients with primary insomnia and suggest that gaboxadols may be a useful treatment for insomnia.
Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial.
- R. Keefe, Philip D. Harvey, R. Luthringer
- Psychology, MedicineThe Journal of clinical psychiatry
- 15 May 2018
Results suggest a possible benefit of MIN-101 on cognitive performance in individuals with schizophrenia with stable positive symptoms and concurrent clinically significant negative symptoms.
The selective FXR agonist EYP001 is well tolerated in healthy subjects and has additive anti-HBV effect with nucleoside analogues in HepaRG cells
Pharmacokinetic profile of SKP‐1041, a modified release formulation of zaleplon
- D. Greenblatt, J. Harmatz, C. Staner
- Biology, ChemistryBiopharmaceutics & drug disposition
- 20 September 2011
Two investigations aimed to define the pharmacokinetic profile of a modified‐release preparation of zaleplon (SKP‐1041) and found no significant differences between the two preparations.
Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia
- J. Lundahl, L. Staner, C. Staner, H. Loft, S. Deacon
- Medicine, PsychologyPsychopharmacology
- 27 July 2007
Acute administration of gaboxadol improves sleep maintenance and enhances SWS in a dose-dependent manner in adult patients with PI and was generally well tolerated with almost exclusively mild to moderately severe adverse events (AEs).